Tianjin TEDA Biomedical Engineering Company Limited (TEDA Biomedical) issued a Positive Profit Alert indicating a sharp turnaround for the six months ended 30 June 2026.

Revenue is projected at RMB290.00 million to RMB300.00 million, up approximately 28%–33% from RMB226.00 million in the same period of 2025. Net profit attributable to owners is expected to reach RMB7.00 million–RMB10.00 million, reversing a RMB6.00 million loss a year earlier and implying year-on-year growth of about 209%–256%.

Management attributes the improved performance primarily to rapid expansion of the Group’s AI Life Healthcare Business, which generated an estimated RMB100.00 million–RMB110.00 million in revenue and RMB10.00 million–RMB12.00 million in attributable profit during the period.

The company noted that the figures are based on unaudited management accounts and may be adjusted. Full interim results for the first half of 2026 are scheduled for release on 31 August 2026.

TEDA Biomedical advised shareholders and potential investors to exercise caution when dealing in its securities until the official interim results are published.